Lingus schreef op 16 oktober 2019 19:57:
HitGen, a Chengdu small molecule discovery company, has been approved for a $97 million IPO on Shanghai's new Science and Technology Innovation Board. HitGen has built a DNA-encoded library that contains nearly 400 billion novel, diverse, drug-like small molecule and macrocyclic compounds. The company is a partnering wonder, having formed more than 60 drug discovery partnerships with a collection of well-known China and global pharmas, including big pharma companies. It has also developed its own portfolio of 20 candidates for various cancer, cardiovascular, inflammatory and metabolic indications.
Bron:
seekingalpha.com/article/4276258-week...With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening.
The platform is fast becoming a staple in drug discovery organizations, having hovered on the periphery as a rarely used tool for difficult-to-drug targets.
DNA-encoded library (DEL) technology can generate and screen diverse small molecule libraries that are orders of magnitude larger than those processed by more established methods, without increasing cost or time.
HitGen CEO Jin Li told BioCentury typical high throughput screening (HTS) methods are limited to millions of compounds because of costs. “Doing billions of molecules in that same fashion would bankrupt the whole industry.”
The company has over 300 billion small molecules in its libraries and is on track to hit one trillion by 2019.
Bron:
www.biocentury.com/bc-innovations/too...Partners onder meer: Gilead, Almirall, Mitsubishi Tanabe, Biogen, Sun Pharma.
Met wat ik er over lees, is HitGen een extreem efficiënte ontwikkelplatform voor kleine moleculen. Hiermee breidt Galápagos zijn ontwikkelcapaciteiten drastisch uit.